Secukinumab for the treatment of SAM syndrome associated with desmoglein-1 deficiency

Br J Dermatol. 2021 Apr;184(4):770-772. doi: 10.1111/bjd.19684. Epub 2020 Dec 28.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized*
  • Dermatitis, Exfoliative*
  • Desmogleins
  • Humans

Substances

  • Antibodies, Monoclonal, Humanized
  • Desmogleins
  • secukinumab